This episode is about hope, and about a different way of thinking about cancer treatment.

My guest is Dr. Øystein Rekdal, CEO and co-founder of Lytix Biopharma. Øystein is a scientist and leader who has spent decades studying how the immune system works - and how it can be helped to recognize and fight cancer more effectively.

Rather than focusing only on destroying tumors, Lytix is working on therapies designed to wake up the immune system and help it remember cancer as a threat. It’s an approach that aims not just to treat disease, but to support the body’s own ability to respond.

This is a conversation for anyone who wants to better understand where cancer care is headed, and why there’s real reason for optimism.

InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.

In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.

EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.

Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

In this episode of Rx for Biotech, host Chris Leidli sits down with Dr. Frank Bedu-Addo, CEO of PDS Biotechnology, to discuss how the company is reimagining immunotherapy with its proprietary Versamune® T-cell activating platform.

Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.

Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies.

In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.

In this podcast episode, Dr. Kilian Kelly, CEO of Cynata Therapeutics, discusses the future of regenerative medicine! Discover how mesenchymal stem cells (MSCs)—powerful cells that repair and regenerate tissues—are revolutionizing treatments for a range of diseases. Dr. Kelly shares insights on Cynata’s groundbreaking Cymerus™ platform and the exciting potential of MSC therapies.